From the 80 Rising Stars selected to pitch at Nordic Life Science Investment Day this week, one company from each track was selected as the category winner. This year, one of three NLSInvest Rising Star Award Winners is ApoGlyx, starting up at Medicon Village six years ago.
Over 150 Nordic companies applied to the launch of the first-ever Nordic Life Science Investment Day, NLSInvest. Following a long review of the applications by a pan-Nordic committee of industry leaders, 80 Rising Stars were ultimately selected to pitch to investors across three dedicated tracks: biotech/pharma, medtech/diagnostics and digital/e-health.
Apoglyx is developing small molecule inhibitors for Aquaporin-9. Aquaporins have been well recognized as important drug targets. Apoglyx’s most advanced approach targets sepsis, for which there is currently no cure.
ApoGlyx was founded in 2015 based on ten years of research by CEO Dr. Michael Rützler and Professor Søren Nielsen, MD, at Aarhus University, together with the group of Prof. Per Kjellbom from Lund University that led to the discovery of small molecule aquaporin-9 inhibitors. To commercialize their idea the researchers turned to Lund University Innovation System, where they started working with Red Glead Discovery at Medicon Village. In October 2015 Red Glead Discovery and the researchers founded ApoGlyx.
Also Medicon Village members PharmNovo, Xinnate and Gedea Biotech were three of the 80 rising stars joining NLSInvest Day.
Congratulations to all!